Conventional neurology has made extraordinary advances in diagnosis and in the management of neurological disease. The ability to image the brain and spinal cord with precision, to identify autoimmune mechanisms, to characterize genetic profiles, and to use disease-modifying medications for conditions like multiple sclerosis represents genuine progress. At the same time, the honest reality is that for many neurological conditions, conventional medicine is primarily disease management rather than disease reversal. Medications control symptoms and slow progression. Few have the ability to restore function that has already been lost.
This gap between what is needed and what conventional neurology currently offers has created a substantial population of patients who are informed, engaged, and actively seeking additional options. Nashville and Middle Tennessee have a growing number of providers exploring how regenerative medicine tools, particularly mesenchymal stem cell (MSC) therapy and platelet-rich plasma (PRP), intersect with neurological health.
This article covers what is being explored, where the evidence is credible, and how to evaluate providers and claims in a field where both promising science and significant overstatement coexist.
Why Neurological Conditions Are Increasingly Being Addressed in Regenerative Settings
The Gap Between Conventional Neurology and Patient Needs
Neurology’s diagnostic toolkit is more powerful than its therapeutic toolkit in many disease categories. A skilled neurologist can precisely characterize a patient’s MS lesion burden, map peripheral nerve conduction velocity, and identify patterns of neurodegeneration that predict disease course. What they frequently cannot offer is a treatment that reverses what has already been damaged.
Patients with peripheral neuropathy, for example, are typically offered medications that modulate the pain signal (gabapentin, pregabalin, duloxetine, amitriptyline) rather than treatments directed at the nerves themselves. These medications do not repair nerve damage. They alter the nervous system’s processing of the pain those nerves generate. For many patients, especially those with progressing neuropathy or significant quality-of-life impairment, the pharmacological toolkit eventually reaches its limits.
Patients with traumatic brain injury or post-stroke sequelae face a similar picture. Rehabilitation is the primary intervention after the acute phase, and it is genuinely valuable. But neurological recovery through rehabilitation is slow, has a ceiling that varies by individual and injury severity, and does not address the cellular environment in which recovery is occurring.
This is the context into which regenerative medicine has moved. The biological properties of MSCs, specifically their secretion of neurotrophic factors and their anti-inflammatory paracrine signaling, have generated a body of preclinical research suggesting that these cells may support nerve survival, reduce neuroinflammation, and in some contexts promote axonal repair. The translation from animal models to human clinical outcomes is where the landscape becomes significantly more complex, and where honest communication about evidence levels is essential.
What Biological Interventions Are Being Explored
Mesenchymal stem cells (MSCs) are the primary regenerative tool with relevance to neurological applications. They are not neurons, and they do not become neurons after injection. Their neurological relevance comes from their paracrine secretome: the collection of signaling molecules, growth factors, cytokines, and extracellular vesicles they release into the surrounding environment.
The neurotrophic factors secreted by MSCs include brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and neurotrophin-3 (NT-3). These are molecules that support neuron survival, axonal growth, and myelin maintenance. Published research in animal models consistently shows that MSC-derived trophic factors support nerve regeneration in peripheral nerve injury models and reduce lesion volume in brain injury models.
MSCs also exert significant anti-inflammatory effects. Neuroinflammation, the activation of microglial cells and the production of inflammatory cytokines in the nervous system, is a driver of ongoing damage in many neurological conditions including MS, TBI, and neurodegenerative disease. MSC-derived cytokines such as TGF-beta and IL-10 suppress this inflammatory activity, at least in experimental settings.
The delivery route is an active variable in neurological MSC research. Intravenous delivery allows cells to circulate and home to sites of inflammation, but many cells are filtered out in the lungs before reaching the nervous system. Intrathecal delivery (into the cerebrospinal fluid) places cells closer to the central nervous system but requires a procedure with a different risk profile. Direct injection near peripheral nerves is used for peripheral neuropathy applications. The optimal delivery route for different neurological conditions remains an open question in the published literature.
A critical distinction for patient expectations: neuroprotection, meaning slowing or halting ongoing damage, and neural regeneration, meaning restoring lost function, are different outcomes. Research suggests that the former may be more achievable than the latter with current regenerative approaches. Patients who are hoping for restoration of function that has already been lost should understand this distinction before making any care decisions.
Neurological Conditions Where Regenerative Therapy Is Being Used Near Nashville
Peripheral Neuropathy
Peripheral neuropathy has accumulated more clinical evidence for regenerative intervention than any other neurological application. The most common form is diabetic peripheral neuropathy (DPN), affecting approximately 50% of patients with longstanding diabetes. The condition results from the combined effects of chronic hyperglycemia on nerve blood supply (small vessel disease) and directly on nerve axons and myelin, producing the characteristic stocking-and-glove pattern of numbness, tingling, burning pain, and eventual sensory loss.
Chemotherapy-induced peripheral neuropathy (CIPN) is another significant category. Many widely used chemotherapy agents, including platinum compounds, taxanes, and vincristine, cause peripheral nerve damage that persists long after cancer treatment is complete. Patients living with CIPN frequently report that conventional medications provide only partial relief and that their quality of life remains substantially impaired years after treatment.
Research into PRP for diabetic peripheral neuropathy has produced encouraging early results. A randomized study examining perineural PRP injections (injections adjacent to affected nerves) showed statistically significant improvements in pain and numbness scores compared to patients receiving conventional medical management. The mechanism is thought to involve the growth factors in PRP supporting nerve blood supply and the surrounding tissue environment. This evidence is early-stage, and the body of published trials is not yet large enough to draw definitive conclusions, but the mechanistic rationale is sound and the early clinical signals are promising.
MSC therapy for peripheral neuropathy has been examined in multiple small clinical series. Published case reports and cohort studies have shown improvements in sensory function and pain in diabetic neuropathy patients. Patients report reduced burning pain and improved sensation in affected areas, though individual responses vary considerably. The Stem Cell Therapy Center of Nashville and other area providers have treated peripheral neuropathy cases, and the field is continuing to generate clinical data.
Near Nashville, patients seeking regenerative consultation for peripheral neuropathy can access this care without traveling out of state. A thorough candidacy assessment for neuropathy should include nerve conduction studies or EMG documentation of the neuropathy, identification of the underlying cause, and a realistic discussion of what the evidence currently supports for the specific neuropathy type.
Post-Injury Neurological Recovery
Traumatic brain injury (TBI) and post-stroke recovery represent areas of intense research interest for regenerative medicine, though the clinical evidence at the human trial level is less mature than for peripheral neuropathy.
The biological rationale is well-developed. After TBI, a cascade of secondary injury processes unfolds over days to weeks following the initial impact: neuroinflammation, oxidative stress, blood-brain barrier disruption, and excitotoxicity all contribute to ongoing cell death beyond the primary injury. MSC-derived anti-inflammatory signaling has been shown in animal models to reduce this secondary injury cascade, potentially preserving neurons that would otherwise be lost. Human trials examining MSC delivery in TBI have generally been small and exploratory, with safety established and preliminary efficacy signals present. Randomized controlled trials of sufficient size to draw clinical conclusions are underway but have not yet produced the evidence base that peripheral neuropathy applications have accumulated.
Post-stroke motor and cognitive recovery is an area where timing of intervention appears to be a critical variable. The brain’s neuroplasticity is highest in the weeks immediately following stroke, and the theoretical window for regenerative support of recovery processes may be time-limited. Research in this area suggests that early intervention during the subacute phase (days to weeks post-stroke) may carry more biological rationale than late intervention years after the event, though some patients have shown benefit even with delayed intervention in published series.
Spinal cord injury, specifically incomplete injuries where some motor and sensory function is retained, represents another area of investigation. The preserved neural pathways in incomplete injury provide the substrate for potential enhancement through MSC signaling support. Complete spinal cord injuries, where all pathways are severed, present a more challenging biological target.
Patients in the Nashville area seeking regenerative consultation for neurological injury should approach these conversations with an understanding that the evidence is early, that no outcomes can be guaranteed, and that coordination with their treating neurologist is an essential component of responsible care.
Systemic Conditions with Neurological Components
Multiple sclerosis involves immune-mediated demyelination of central nervous system pathways, producing a wide range of neurological symptoms depending on the location of lesions. The anti-inflammatory properties of MSCs have generated significant interest in MS as a potential application, and several clinical trials have examined MSC therapy in relapsing-remitting MS.
Research suggests that MSC therapy in MS primarily targets the inflammatory component of the disease rather than promoting remyelination of established lesions. For patients in the relapsing-remitting phase, where active inflammation drives new lesions, anti-inflammatory MSC effects may have clinical relevance. For patients with progressive MS, where neurodegeneration rather than active inflammation is the dominant mechanism, the biological rationale is less clear.
Autonomic neuropathy, affecting the nerves that regulate involuntary functions including heart rate, blood pressure, digestion, and sweating, is an area where patients frequently report that conventional management falls short. Small fiber neuropathy, affecting the thin unmyelinated and thinly myelinated nerve fibers responsible for pain, temperature, and autonomic function, is increasingly recognized as a significant and poorly treated condition. Both conditions are areas where regenerative consultation is being sought, though the published evidence base is smaller than for large-fiber peripheral neuropathy.
How to Evaluate Neurological Regenerative Claims
Where Evidence Is Established vs. Still Emerging
The evidence landscape for neurological applications of regenerative medicine has a clear gradient, and understanding that gradient is essential for calibrated expectations.
Peripheral neuropathy, particularly diabetic peripheral neuropathy, has the most developed clinical evidence among neurological applications. Multiple clinical series and several controlled trials show consistent patterns of improvement in pain and sensory function in meaningful proportions of patients. This is not established mainstream medicine, but the evidence is more mature than in other neurological applications.
TBI and post-stroke recovery represent actively studied but early-phase territories. Human trials have demonstrated safety. Preliminary efficacy signals exist. The evidence is not yet at the level that supports confident prediction of outcomes in individual patients. This should be communicated honestly in any responsible clinical consultation.
Neurodegenerative conditions, including Parkinson’s disease, ALS, and Alzheimer’s disease, present the most challenging evidence situation. Preclinical animal research in these conditions has shown promising results with MSC intervention. Human clinical trials have been initiated, but the evidence base at the human level remains minimal and does not support confident clinical claims. Patients with these diagnoses who are seeking regenerative consultation should be informed that the evidence is very early, that no disease modification has been demonstrated in human trials, and that the primary risk of consulting an unscrupulous provider in this space is that hope is sold alongside interventions whose efficacy is not supported by the available data.
What Language Responsible Clinics Use and What Should Raise Concern
The language a regenerative clinic uses when discussing neurological applications is one of the most reliable quality signals available before a clinical consultation.
Responsible language for neurological applications sounds like:
“We are seeing some patients with peripheral neuropathy report improvements in pain and sensation. The published evidence for this application is early-stage, and individual responses vary significantly.”
“The evidence for your specific diagnosis is limited at this point. Here is what we know from published studies and here is where the evidence has not yet been established.”
“We strongly recommend that you continue working with your neurologist alongside any treatment here. We will coordinate with your neurology team.”
“We cannot tell you that we can stop your condition from progressing. What we can tell you is what the current evidence suggests about biological support for the nervous system and what we have seen in patients with similar presentations.”
Language that should raise serious concern:
“Cure” applied to any progressive neurological condition. No regenerative therapy has been shown to cure MS, Parkinson’s, ALS, or Alzheimer’s disease.
“Reversal” of established neurodegeneration. This claim has not been demonstrated in human clinical evidence.
“Proven effective” for any neurodegenerative condition. Human evidence is far too limited to support this language.
“Your neurologist doesn’t know about this” or suggestions that conventional neurology has suppressed or ignored this approach. This type of framing is a reliable indicator of a practice operating outside legitimate scientific discourse.
Questions That Reveal Whether a Clinic Is Being Honest About Limits
The questions a patient asks at a neurological regenerative consultation reveal as much about the clinic as the answers they receive.
Ask: “What published evidence exists specifically for my diagnosis?” The answer should reference specific studies, acknowledge their limitations, and distinguish between conditions where the evidence is stronger (peripheral neuropathy) and those where it is weaker (neurodegenerative disease).
Ask: “Are you enrolled in an IRB-approved protocol for this application?” Independent Review Board oversight means a clinic is conducting its neurological regenerative work within a formal research framework, with ethics oversight, informed consent documentation, and systematic outcome tracking. Not all responsible clinics will be enrolled in formal research protocols, but the answer to this question reveals whether they are contributing to the evidence base or simply delivering treatments without structured outcome tracking.
Ask: “What is the realistic goal for someone with my condition?” The answer should be calibrated to the evidence. For peripheral neuropathy, “meaningful improvement in pain and sensation in many patients, with a realistic expectation of partial response rather than complete resolution” is an honest answer. For a neurodegenerative condition, “potential support for nervous system health through anti-inflammatory mechanisms, with no expectation of disease reversal and a genuine acknowledgment that we are in very early evidence territory” is an honest answer. Beware of goals that sound more definitive than the evidence supports.
Ask: “Should I continue seeing my neurologist alongside treatment here?” The only appropriate answer is yes. Any provider who suggests that regenerative treatment is a substitute for ongoing neurological care is not operating in the patient’s interest.
Finding the Right Provider in the Nashville Area for Neurological Cases
Physician Background That Matters for Neurological Applications
Neurological regenerative cases are more clinically complex than peripheral joint cases. The physician conducting the candidacy assessment should be comfortable interpreting neurological diagnostic information, familiar with the published evidence for neurological regenerative applications, and experienced in coordinating care with neurologists.
Physical medicine and rehabilitation (PM&R) physicians often have the strongest background in the intersection of neurological function and regenerative intervention, given their training in rehabilitation medicine, electrodiagnostic testing (EMG and nerve conduction studies), and functional outcome assessment. Pain medicine physicians with neuromodulation experience also bring relevant background, particularly for cases involving peripheral neuropathy or post-injury nerve pain.
Experience with actual neurological patient cases in a regenerative setting matters as much as training background. Ask the physician how many patients with your specific condition they have treated, what patterns they have observed, and what they have learned about which patient characteristics seem to be associated with better or worse response.
A physician who takes these questions seriously and answers them with appropriate nuance is demonstrating the clinical rigor that neurological cases require.
What a Proper Neurological Candidacy Assessment Should Include
The neurological regenerative candidacy assessment differs from a musculoskeletal assessment in several important respects.
A detailed neurological history is foundational. This includes the onset of symptoms, the pattern of progression, the results of prior neurological workup, the diagnoses that have been established or considered, and the medications and other treatments already being used. A patient with peripheral neuropathy who has not had nerve conduction studies should not receive a regenerative recommendation before that diagnostic gap is closed.
Review of prior neurological testing is non-negotiable for neurological cases. Nerve conduction studies and EMG for peripheral neuropathy, brain and spinal MRI for TBI and MS cases, and relevant genetic testing for hereditary conditions all provide information that affects candidacy and protocol design.
Current neurological treatment and medications need to be reviewed carefully. Disease-modifying therapy in MS, for example, represents an active immunological intervention that may interact with the MSC immune-modulating properties being introduced. Coordination with the treating neurologist on medication timing relative to any regenerative procedure is appropriate.
A transparent, structured discussion of the evidence for the patient’s specific condition is part of the consultation, not supplemental to it. Goals should be defined explicitly and documented: what will be tracked, how improvement will be measured, and what the follow-up timeline looks like.
Coordination with the treating neurologist should be an active part of the plan, not a casual suggestion. A regenerative physician handling neurological cases should be comfortable sending consultation notes to the patient’s neurologist and engaging in dialogue about the clinical rationale for the proposed intervention.
The standard of rigor required for neurological cases in the Nashville regenerative medicine ecosystem is higher than for musculoskeletal applications, and patients considering this type of care should hold providers to that standard as a basic quality expectation.
Sources
- Perineural Platelet-Rich Plasma for Diabetic Neuropathic Pain, Could It Make a Difference? (PubMed)
- Human Studies of the Efficacy and Safety of Stem Cells in the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis (PubMed)
- Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions (PMC)
- Therapeutic Potential and Challenges of Mesenchymal Stem Cells in Neurological Disorders: A Concise Analysis (PubMed)
- Stem Cell Therapy for Degenerative Disc Disease: Bridging the Gap Between Preclinical Promise and Clinical Potential (PMC)
- The Role of NAD+ in Regenerative Medicine (PMC)
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.